The Cost of Complications Following Major Resection of Malignant Neoplasia by Zogg, Cheryl K. et al.
The Cost of Complications Following Major Resection of 
Malignant Neoplasia
Cheryl K. Zogg, MSPH, MHS1,2, Taylor D. Ottesen, BS1, Kareem Kebaish, BS1, Anoop 
Galivanche, BS1, Shilpa Murthy, MD, MPH2,3, Navin R. Changoor, MD2, Donald L. Zogg, 
MD4, Timothy M. Pawlik, MD, PhD, MPH, MTS, FACS5, and Adil H. Haider, MD, MPH, FACS2
1.Yale School of Medicine, New Haven, CT
2.Center for Surgery and Public Health, Harvard Medical School and Harvard T.H. Chan School of 
Public Health, Department of Surgery, Brigham and Women’s Hospital, Boston, MA
3.Department of Surgery, Indiana University School of Medicine, Indianapolis, IN
4.Minnesota Gastroenterology, PA, Saint Paul, MN
5.Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH
Abstract
Background: Rising healthcare costs have led to increased focus on the need to achieve a higher 
“value of care.” As value-maximization efforts expand to include more complex surgical patients, 
evidence to support meaningful implementation of complication-based initiatives is lacking. The 
objective of this study was to compare incremental costs of complications following major 
gastrointestinal (GI) resections for organ-specific malignant neoplasia using nationally-
representative data.
Methods: National (Nationwide) Inpatient Sample data, 2001-2014, were queried for adult 
(≥18y) patients undergoing major resections for malignant neoplasia. Based on system-based 
complications considered relevant to the long-term treatment of GI disease, stratified differences in 
risk-adjusted incremental hospital costs and complication probabilities were compared. 
Differences in surgical outcomes and costs over time were also assessed.
Results: A total of 293,967 patients were included, weighted to represent 1,408,117 patients 
nationwide. One-fourth (26.1%, 95%CI: 25.7-26.4%) experienced ≥1 pre-discharge complication 
(range: 45.3% esophagectomy to 24.0% rectal resection). Resultant annual risk-adjusted 
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incremental hospital costs totaled $540 million nationwide (19.5% of the overall cost of care and 
an average of $20,900 per-patient). Costs varied substantially with both cancer/resection type and 
complication group, ranging from $76.7 million for colectomies with infectious complications to 
$0.2 million for rectal resections with urinary complications. For each resection type, infectious 
($154.7 million), GI ($85.5 million), and pulmonary ($77.9 million) complications were among 
the most significant drivers of increased hospital cost.
Conclusions: Quantifying and comparing the impact of complications on an indication-specific 
level in more complex patients offers an important step toward allowing providers/payers to 
meaningfully prioritize the design of novel and adaptation of existing value-maximization 
approaches.
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Introduction
In 2015, healthcare spending in the United States (US) reached a record high of $3.2 trillion1
—a number that is projected to rise by an average of 5.8% per year,2 grow at a rate nearly 
five-times that of the current US total gross domestic product (GDP),3 and reach >20% of 
the US GDP by 2025.2 Already a source of national concern, rising healthcare costs have led 
to increased focus on the need to achieve a higher “value of care.”4 Defined as the sum of 
quality and outcomes divided by cost,4 the concept of value represents a somewhat nebulous 
notion of the need to achieve a better understanding of the association between costs and 
quality. Balance between cost and quality, combined with an awareness of how they affect 
patient outcomes, is critical when considering cost-reduction strategies capable of 
simultaneously maximizing the quality of care.5-10
Prior approaches to improve value in surgery have increased awareness of healthcare 
spending and changed how providers conceptualize efforts to account for quality.10 
However, many value-maximization approaches, including pay-for-performance (receipt of 
financial/non-financial (dis)incentives based on outcomes achieved in line with 
predetermined metrics), have been widely criticized.8, 10-12 Government programs13 based 
on pay-for-performance metrics have led to questions about which hospitals and patients 
they most affect.14-16 Other approaches, such as the use of bundled payments (payment for 
an episode of care versus individual line items)17-19 and accountable care organizations 
(groups of hospitals/providers who coordinate their efforts)20-22 are thought to have the 
potential to be viable surgical reimbursement models.18 Although, future studies and 
“frameworks to characterize the strategic advantages and disadvantages” of each are needed 
in order to understand their full impact.22 Lacking such a framework, evidence supporting 
effective prioritization remains scarce at a time where the success of value-maximization 
depends on an ability to account for what leads to the growing and high healthcare costs 
observed.10
Among cancer patients where annual spending is projected to reach $173 billion dollars 
within three years,23 relative increases in index hospital costs upwards of 50% have been 
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reported when complications occur.24 For general surgery patients, complications are 
thought to play an equally critical role, increasing both hospital costs and the probability of 
poor patient outcomes.6,7 Expanding efforts to promote value within both groups will have 
to take into account complications in order to allocate resources in evidence-based ways. 
The challenge lies in knowing how it ought to be done. Prior efforts to guide value-
maximization around complications in surgery have often been limited by a lack of 
standardized definitions and complication groupings. These data have created only a limited 
understanding of the interplay between complications, costs, and outcomes on a national 
scale.
Thus, today, as the focus of surgical value-maximization begins to expand from its initial 
emphasis on colectomy and sub-specialty CABG and THA/TKA care to include a broader 
array of surgical procedures,25,26 including those associated with surgical oncology,27-32 
research is needed in order to understand the impact of complications and guide the 
development of novel and adaptation of existing value-maximization approaches in 
meaningful ways. The objective of this study was to provide a framework to help achieve 
this end by comparing incremental costs of complications following major gastrointestinal 
(GI) resections for organ-specific malignant neoplasia using nationally-representative data.
Methods
Data from the 2001-2014 National (Nationwide) Inpatient Sample (NIS) were queried for 
hospitalizations with primary International Classification of Diseases, 9th revision, Clinical 
Modification (ICD-9-CM) diagnosis codes for malignant neoplasia (Supplemental Table 1). 
Identified hospitalizations were grouped by organ-site into esophageal, gastric, colonic, 
hepatic, pancreatic, and rectal cancer cases. Hospitalizations were excluded if they were 
missing outcome or covariate information (total 2.8%). Hospitalizations for patients aged 
<18y and for patients who did not undergo a major surgical resection based on reported 
ICD-9-CM procedure codes were also excluded (Supplemental Table 2; Figure 1). Missing 
information for race/ethnicity was addressed using a missing indicator variable to account 
the approximately 20% of states in NIS that do not report race/ethnicity.
NIS is the largest publically-available all-payer inpatient database in the US, yielding 
national estimates of inpatient stays.33 Unweighted, it contains data from >7 million annual 
hospital visits. HCUP-defined design-weights are used to approximate national estimates, 
accounting for >36 million hospitalizations each year. Prior to 2012, NIS represented a 20% 
stratified-sample of hospitals selected based on geographic region, ownership-control, urban/
rural location, teaching status, and number of hospital beds. Since 2012, the database has 
become a 20% stratified sample of hospital discharges from the majority of hospitals in the 
US.33 Application of trend weights allows for consistent reporting of nationally-weighted 
estimates across both iterations of database years (2001-2011, 2012-2014). Available data-
elements include information on patient age, sex, race/ethnicity, primary payer, length of 
stay (LOS), total charges, disposition, hospital characteristics, and up to 25 ICD-9-CM 
diagnosis and 15 ICD-9-CM procedure codes.
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Information abstracted on patient and hospital characteristics included: age (18-25, 26-35, 
36-45, 46-55, 56-65, 66-75, >75y), sex, NIS-defined race/ethnicity (non-Hispanic White, 
non-Hispanic Black, Hispanic, non-Hispanic other, unreported/unknown), insurance status 
(private, government, uninsured), NIS-defined income quartile, elective versus emergent/
urgent indication, primary diagnosis, calculated Charlson Comorbidity Index (CCI: 0, 1-2, 
≥3), year, hospital volume (high, low; NIS-defined large, small/medium bedsize), hospital 
teaching-location (rural, urban teaching, urban non-teaching), and hospital region 
(Northeast, Midwest, South, West). Patients were assessed for the occurrence of 
complications using physiological system-based codes defined in conjunction with the 
research department of Minnesota Gastroenterology, P.A. These codes were chosen with the 
specific intention of creating a set of ICD-9-CM system-based complications relevant to the 
long-term treatment of patients undergoing GI procedures.10 Complication groups included: 
mechanical wounds (e.g. hematoma, seroma), infections (e.g. sepsis/septicemia), 
complications during surgery (e.g. accidental puncture or laceration complicating surgery), 
and urinary (e.g. postoperative urinary tract infection), pulmonary (e.g. ventilator associated 
pneumonia, post-procedural aspiration pneumonia), gastrointestinal (e.g. postoperative ileus, 
postoperative small bowel obstruction), cardiovascular (e.g. postoperative deep vein 
thrombosis), and systemic (e.g. postoperative shock: septic or hypovolemic) complications. 
Corresponding secondary diagnosis codes are presented in Supplementary Table 3. 
Hospitalized patients included in the final analysis were dichotomized based on occurrence 
of individual complication groups and ≥1 complication(s) overall.
Total index hospital costs in 2017 US dollars (USD) served as the study’s primary outcome 
measure. NIS-provided total hospital charges in 2001-2014 USD were converted to total 
hospital costs using cost-to-charge ratios. Values were converted to 2017 USD using annual 
hospital consumer-price-indices. Secondary measures included assessment of surgical 
outcomes: non-routine discharge (other than to home under self-care), in-hospital mortality, 
and index LOS.
Statistical analyses
Differences in patient- and hospital-level factors were compared between patients with and 
without complications using Chi-squared tests. Binary outcomes were compared using crude 
and risk-adjusted logistic regression to give odds ratios (OR) and 95% confidence intervals 
(95%CI). The continuous outcomes, total index hospital cost and LOS, were both right-
skewed. To account for the non-normal distributions of these outcome measures, modified 
Park tests were used to determine appropriate modeling strategies. Both conformed to 
natural logarithm-transformed gamma distributions. Crude and risk-adjusted generalized 
linear models based on these parameters were used to model the continuous distributions. 
Calculation of post-estimation average marginal effects yielded predicted mean differences 
and 95%CI for each.
Risk-adjusted incremental costs and complication probabilities for each cancer/resection 
type and complication group were calculated in an analogous manner. Determination of 
incremental effects included risk-adjustment for the potential influence of multiple 
complications by adding the occurrence of other complications to the complication group-
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specific model in order to yield isolated, complication group-specific effects. Aggregate 
measures of the total national burden were obtained by combining risk-adjusted information 
on complication group prevalence and incremental cost.
All models were checked for multicollinearity and appropriateness of fit. The models were 
weighted with NIS-provided design-weights (including corrected trend weights from 
2001-2011, strata sampling from 2001-2014, and hospital clustering from 2001-2014) using 
survey commands in Stata in order to account for patient clustering within hospitals and 
attain nationally-weighted effects. Data analyses were performed using Stata Statistical 
Software: Release 14.2 (College Station, TX). Two-sided p-values were considered 
significant. The study was approved by the Yale Human Investigation Committee.
Results
Epidemiologic data
A total of 293,967 patients were included. The weighted data represented 1,408,117 patients 
nationwide (Figure 1). The most prevalent group underwent colonic resections (n=217,939, 
74.1%), followed by gastric (n=25,552, 8.7%), rectal (n=17,503, 6.0%), and pancreatic 
(n=16,338, 5.6%) resections. A total of 8,803 patients (3.0%) underwent hepatectomy, and 
7,832 (2.7%) underwent esophagectomy. Overall, a risk-adjusted 26.1% (95%CI: 
25.7-26.4%) of patients experienced ≥1 pre-discharge complication(s) (Table 1). 
Documented complications most frequently included gastrointestinal (11.6%[11.3-11.8%]]), 
infectious (6.7%[6.6-6.9%]), and pulmonary (5.0%[4.8-5.2%]) manifestations. 
Complications were most prevalent among esophageal (45.3%[43.8-46.9%]), gastric 
(33.6%[32.8-34.5%]), and pancreatic (34.0%[32.7-35.3%]) cancer cases. Complete risk-
adjusted distributions of complication prevalences for each cancer/resection type and 
complication group are presented in Table 1.
Overall, the occurrence of complications became more prevalent as patients aged, rising 
from 20.7% among patients aged 18-45y to 30.1% among patients aged >85y (Table 2). 
Complications were more likely among males versus females, 28.8% versus 23.2%, (a trend 
which persisted for each complication group); patients with a higher CCI, ≥7: 28.9% versus 
≤2: 24.3%; and patients with an emergent/urgent versus elective indication, 30.4% versus 
24.4%. Limited differences were noted based on patient race/ethnicity, income, or insurance 
type. Relative to privately-insured patients, however, uninsured patients were 37.3% more 
likely to experience an infectious complication (8.1% versus 5.9%). Differences in hospital 
characteristics, while statistically significant, were largely comparable across groups.
Differences in hospital costs by complication type and primary organ resected
In 2017 USD, total annual index hospital costs for major oncologic GI malignant resections 
in the US totaled an average of $2.75 billion (Figure 2A). Complications accounted for 
19.5%—an average of $540 million nationwide per year. By cancer/resection type, 
complications accounted for 30.1% of esophageal, 26.5% of gastric, 16.3% of colonic, 
21.2% of hepatic, 22.1% of pancreatic, and 21.6% of rectal cancer costs.
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Individual risk-adjusted incremental complication costs on a per-patient level are presented 
in Table 3. Overall, the occurrence of any isolated complication increased index hospital 
costs by an average of $20,900 (95%CI: $20,300-21,500)—a value which ranged from 
$12,700 ($10,700-14,700) among rectal resections to $40,400 ($37,400-43,400) for 
esophageal resections. Infectious complications were the single-most expensive 
complication with an average of $21,600 (95%CI: $21,000-22,200; range: rectal-$ 14,200 to 
esophageal-$46,600) in added total hospital costs. This was followed by pulmonary 
complications with average costs of $16,800 (95%CI: $16,200-17,400; range: rectal-$4,900 
to esophageal-$21,700) and mechanical wounds with average costs of $13,600 (95%CI: 
$12,900-14,300; range: rectal-$ 10,500 to esophageal-$24,600).
When national prevalences were taken into account (Figure 2B), infectious complications 
again contributed the largest total amount, costing hospitals and payers an additional $154.7 
million nationwide per year (36.9% of the total incremental complication cost). GI 
complications contributed an additional $85.5 million per year (20.4% of the total 
incremental complication cost). Mechanical wounds cost an average of $29.3 million 
(7.0%), urinary $5.3 million (1.3%), pulmonary $77.9 million (18.6%), cardiovascular $30.2 
million (7.2%), systemic $6.0 million (1.4%), and surgical $30.6 million (7.3%). By 
resection type, the impact of complications ranged from $76.7 million per year for colonic 
resections with infectious complications to a more modest $0.2 million for rectal resections 
with urinary complications. For each resection type, infectious, GI, and pulmonary 
complications were among the most significant drivers of overall increased total index 
hospital costs.
Changes over time
Annual incremental complication costs from 2001-2014 are presented in Figure 2C. From 
2001-2006, costs ranged from approximately $530 million to $570 million nationwide per 
year. They increased slightly between 2007-2011, $560 million to $640 million, before 
beginning to decrease from 2012-2014, eventually reaching an annual incremental index 
hospital cost of $460 million in 2014. Overall trends closely paralleled changes in 
colectomies, which dropped from an average of $280 million to $320 million per year 
between 2001-2009 to approximately $220 million per year in 2014 (Figure 2C).
Surgical outcome regression results
Risk-adjusted differences in surgical outcomes are presented in Table 4. Relative to patients 
without a complication, patients with any complication (OR[95%CI]: 2.65[2.58-2.72]) and 
with each complication type (range: infectious-5.18[4.91-5.46] to urinary 1.51[1.40-1.63]) 
were significantly more likely to require non-routine discharge. In addition, patients who 
experienced a complication had 6.08 times higher risk-adjusted odds of death (any 
complication OR[95%CI]: 6.08[5.79-6.39]; infectious: 8.60[8.13-9.11]) and index LOS that 
were longer by an average of 5.5 days (any complication predicted mean difference 
[95%CI]: 5.5 [5.4-5.6] days; infectious: 6.5 [6.3-6.6] days).
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Discussion
The study investigated incremental costs of complications among organ-specific sites of 
major GI resection for malignant neoplasia, demonstrating a significant association between 
complications and increased costs of care. Each year, complications within this population 
cost hospitals and payers an average of $540 million, raising index hospital costs by a risk-
adjusted average of 19.5% (range: 16.3% colectomy to 30.1% esophagectomy). 
Complications were associated with 3-times higher risk-adjusted odds of non-routine 
discharge, 6-times higher odds of in-hospital death, and LOS that were longer by an average 
of >5 days.
While significant contributors to increased hospital costs and poor patient outcomes in each 
type of resection considered, not all complications were equal. Important differences based 
on the type of complication and type of operation were found. For example, among patients 
with esophageal malignancies undergoing esophagectomy, 45.3% experienced ≥1 pre-
discharge complication (21.2% pulmonary, 12.9% infection, 11.2% GI, etc.). Complication-
specific incremental costs for esophagectomy ranged from $9,400 (cardiovascular) to 
$46,600 (infection) per patient. Among patients with colonic malignancies undergoing 
colectomy, a more modest 24.4% of patients experienced ≥1 pre-discharge complication 
(12.0% GI, 5.9% infection). Complication-specific incremental costs in this group ranged 
from $3,100 (urinary) to $17,500 (infection) per patient.
Such a wide range of costs underscores the need for value-maximization approaches that 
reflect the spectrum of adverse outcomes associated with surgical oncology care.27-32 
Lacking this direction, well-intended interventions can easily go astray as has been 
demonstrated by the early surgical pay-for-performance complication-tracking established 
by Medicare and other partner organizations in 2006. The resultant program which targeted 
surgical site infections, venous thromboembolism, myocardial infarction, pneumonia, and 
catheter-associated urinary tract infections has been widely-criticized for overlooking 
important complications relevant to both elective10,34 and emergent8 indications and for 
focusing too much on urinary complications which minimally contributed to the overall cost 
of care.10 In the current study, urinary complications accounted for only 1.3% of incremental 
increases in index hospital costs. Where they did occur, they either contributed no significant 
additional incremental cost or a comparatively small additional amount that ranged from 
approximately $3,000 per patient for patients undergoing a colonic resection (and, 
correspondingly, any operation overall) to $8,000 for liver and pancreatic resections. The 
difference in magnitude of the effect of urinary complications between these three groups 
likely reflects underlying differences in the fragility and physiologic reserves of the 
corresponding patients. Across all complication types, hepatic-pancreatic-biliary (HPB) 
patients were more prone than other cancer patients to expensive increases in incremental 
index hospital costs when complications occurred. More recent initiatives targeting an array 
of complications among THA/TKA patients under Medicare’s Hospital Value Based 
Purchasing Program35, 36 and surgical site infections among all surgical patients under the 
Hospital Acquired Condition Reduction Program37 have met with more promising albeit still 
mixed success.
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Declining trends in annual costs of complications for colon cancer patients suggest the 
potential early success of some value-maximization approaches. Drops since 2008 coincide 
with the timing of bundled-payment introduction and a widespread national change in the 
discourse surrounding the quality of the procedure. The extent to which this change can be 
attributed to either factor remains deeply contested 19,38,39 and is likely to be further 
confounded by parallel efforts to promote reductions in infections among elective colectomy 
patients.10 The results of this study noted that for all GI-related surgical oncology patients, 
infection was the highest single contributor to individual patient costs (average incremental 
cost $21,600), followed closely by pulmonary complications ($16,800) and mechanical 
wounds ($13,600). When national prevalences were taken into account, infections again 
contributed the largest total amount, costing an additional $155 million per year (36.9% of 
the total incremental amount). They increased patients’ odds of death 8.60-fold.
The mixed success of prior value-maximization endeavors raises the question, “Where do 
we go from here?” The results of this study build on prior initiatives and a growing body of 
literature criticizing prior initiatives by establishing an evidence-based framework that 
defines meaningful complication-based targets for value-maximization and assessment of 
surgical oncology patients. As efforts to promote value-maximization continue to increase, it 
will be essential to recognize the intricacies of outcomes and care encountered when dealing 
with complex cancer patients. Quality-improvement and cost-reduction approaches must be 
informed in order to account for the challenges of cancer patients’ needs. Related health 
policy ought to reflect similar considerations in order to target finite improvement efforts 
and resources toward areas with the greatest need. In looking at increases in index hospital 
costs upwards of 16 to 30%, the results of this study underscore the importance of including 
complications in ongoing development of quality-improvement assessments and value-
maximization intervention approaches.7-10 Moving forward, as Medicare, professional 
organizations, and individual hospitals strive to address these concerns and increase their 
consideration of outcomes for complex surgical patients, there is a need to focus on both a 
broad array of complications in order to avoid the pitfalls of the 2006 pay-for-performance 
program as well as to hone in on meaningful complications for a given population. Among 
surgical GI oncology patients, one thing is abundantly clear: infections must be controlled.
The study is not without limitations, most of which come from its reliance on national 
administrative claims that can be subject to absent or misreporting of some data. Use of NIS 
allowed for a large, multiyear assessment of complications and costs on a national scale. It 
did not allow for assessment of clinical margins or stage. To help mitigate this concern, 
inclusion criteria were limited to patients with documented malignant neoplasia undergoing 
a major surgical resection of the corresponding organ. Data on costs in NIS are reported as 
charges and converted to costs using hospital-specific cost-to-charge ratios—an imperfect 
measure of individual patient costs and one that precludes a more nuanced assessment of the 
specific components of direct hospital costs. Data on readmissions and indirect hospital 
costs were not able to be assessed.
In conclusion, although value-maximization initiatives have started to account for the 
economic impact of complications, few have directly addressed the range of costs and 
prioritization of appropriate targets in complex surgical fields, leading to a dearth of 
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information on the interplay between complications, costs, and outcomes on a national scale 
and a growing history of heavily-criticized interventions and measures. Quantifying and 
comparing the impact of complications on an indication-specific level in more complex 
patients offers an important step toward allowing providers and payers to meaningfully 
prioritize the design of novel and adaptation of existing value-maximization approaches in 
surgical fields.
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Figure 1. 
Schematic of inclusion and exclusion criteria
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Figure 2. 
A. Total annual index hospital cost for major oncologic malignant resections in the United 
States, 2001–2014. B. Breakdown of annual incremental costs by system-based 
complication group. C. Changes in annual incremental costs overall and for colonic 
resection, 2001-2014
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Table 1.
Risk-adjusted probability of system-based complications (95%CI)A,B
Probability of Complications in Major Oncologic Resections for Malignant Diagnoses
Any complication Mechanical wound Infection Urinary
Esophagus 45.3%
(43.8-46.9%)
4.4%
(3.9-4.4%)
12.9%
(12.0-13.7%)
1.3%
(1.0-1.6%)
Stomach 33.6%
(32.8-34.5%)
3.0%
(2.7-3.2%)
10.8%
(10.4-11.2%)
1.4%
(1.2-1.6%)
Colon 24.4%
(24.0-24.8%)
1.7%
(1.7-1.8%)
5.9%
(5.8-6.1%)
1.4%
(1.3-1.4%)
Liver 25.6%
(24.5-26.7%)
2.4%
(2.1-2.7%)
7.1%
(6.5-7.7%)
1.6%
(1.3-1.8%)
Pancreas 34.0%
(32.7-35.3%)
3.9%
(3.6-4.3%)
12.5%
(11.7-13.2%)
1.5%
(1.3-1.7%)
Rectum 24.0%
(22.3-25.7%)
2.8%
(2.1-3.4%)
5.2%
(4.4-6.1%)
2.3%
(1.7-2.9%)
All operations 26.1%
(25.7-26.4%)
2.0%
(1.9-2.1%)
6.7%
(6.6-6.9%)
1.4%
(1.3-1.5%)
Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
Esophagus 21.2%(19.6-22.8%)
11.2%
(710.3-12.1%)
9.7%
(9.0-10.6%)
1.9%
(1.6-2.3%)
6.3%
(5.7-6.9%)
Stomach 11.0%
(10.3-11.7%)
10.3%
(9.8-10.8%)
5.9%
(5.5-6.3%)
1.7%
(1.5-1.9%)
4.5%
(4.2-4.7%)
Colon 3.7%
(3.6-3.9%)
12.0%
(11.7-12.3%)
3.0%
(2.9-3.1%)
1.0%
(1.0-1.1%)
3.1%
(3.0-3.2%)
Liver 6.3%
(5.7-7.0%)
9.3%
(8.5-10.1%)
3.3%
(3.0-3.7%)
1.2%
(1.0-1.4%)
4.4%
(4.0-4.8%)
Pancreas 7.6%
(7.0-8.3%)
11.5%
(10.6-12.4%)
4.1%
(3.6-4.5%)
1.7%
(1.4-1.9%)
6.0%
(5.6-6.5%)
Rectum 2.5%
(1.8-3.1%)
11.1%
(9.9-12.4%)
2.3%
(1.8-2.9%)
0.3%
(0.1-0.5%)
4.7%
(3.9-5.5%)
All operations 5.0%
(4.8-5.2%)
11.6%
(11.3-11.8%)
3.5%
(3.3-3.6%)
1.1%
(1.1-1.2%)
3.5%
(3.4-3.6%)
A
Models accounted for potential confounding due to patient characteristics (age, sex, race/ethnicity, insurance type, median income quartile, 
indication, primary diagnosis, CCI, and year) and hospital-level factors (hospital volume, teaching-location, and geographical region).
B
Modeling used NIS-provided population weights generalized with STATA’s “svy” command to account for patient clustering within hospital-level 
variables and to extrapolate the sample to a nationally representative version of the US population
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Table 2.
Patient demographic and hospital-level characteristics (all operations; nationally-weighted percentages)
Type of complication
Patient
Characteristic
Any complication Mechanical wound Infection Urinary Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
Age (years)
 18-45 20.7 1.9 6.0 0.8 3.0 9.6 1.5 1.2 3.1
 46-55 22.1 2.1 6.5 0.9 3.9 10.0 1.8 1.2 3.1
 56-65 24.2 2.2 6.9 1.0 4.6 10.6 2.5 1.2 3.3
 66-75 26.9 2.1 7.0 1.5 5.2 12.0 3.8 1.1 3.7
 76-85 28.3 1.9 6.6 1.8 5.6 12.5 4.5 1.1 3.6
 >85 30.1 1.8 7.2 2.0 6.4 13.0 5.1 1.0 3.5
Sex
 Male 28.8 2.5 7.9 1.7 5.7 12.8 3.9 1.2 3.6
 Female 23.2 1.5 5.6 1.1 4.3 10.3 3.1 1.0 3.3
Race/Ethnicity
 Non-Hispanic White 26.1 2.1 6.7 1.4 5.3 11.5 3.6 1.0 3.4
 Non-Hispanic Black 26.2 2.0 7.6 1.2 4.5 11.7 2.9 1.4 3.5
 Hispanic 25.6 2.2 7.7 1.2 5.2 10.8 2.6 1.2 3.4
 Non-Hispanic other 25.0 2.0 7.0 1.6 4.2 10.8 2.9 1.5 3.9
 Unreported 26.4 1.8 6.2 1.3 4.6 12.0 3.5 1.4 3.6
Insurance
 Public 27.8 2.1 7.1 1.6 5.5 12.2 4.0 1.1 3.6
 Private 22.8 1.9 5.9 1.0 4.1 10.5 2.5 1.2 3.2
 Uninsured 23.3 1.8 8.1 0.8 3.6 10.4 2.0 1.2 3.2
 Other 23.7 2.3 6.8 0.9 4.3 10.6 2.2 1.3 3.3
Income quartile (USD)A
 1-38,999 26.7 2.3 7.5 1.3 5.2 11.6 3.1 1.1 3.7
 39,000-47,999 25.7 2.1 6.6 1.4 4.9 11.4 3.3 1.0 3.4
 48,000-63,999 26.2 2.0 6.7 1.4 5.1 11.8 3.5 1.2 3.6
 ≥ 64,000 25.8 1.8 6.4 1.5 4.9 11.5 3.8 1.3 3.3
CCI
 ≤ 2 24.3 1.8 5.9 1.3 4.0 11.6 3.2 1.2 3.4
 3-4 26.4 2.1 6.2 1.4 4.9 11.1 3.8 1.1 3.4
 5-6 27.0 2.2 7.8 1.4 5.8 12.1 3.2 1.2 3.6
 ≥ 7 28.9 2.3 8.2 1.6 6.7 13.4 4.0 1.1 3.5
Indication
 Elective 24.4 1.8 5.5 1.4 4.5 11.1 3.5 1.1 3.5
 Emergent/Urgent 30.4 2.5 9.9 1.3 6.3 12.7 3.5 1.3 3.5
Type of complication
Hospital Characteristic Any complication Mechanical wound Infection Urinary Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
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Type of complication
Patient
Characteristic
Any complication Mechanical wound Infection Urinary Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
Hospital volume
 High volume 26.4 2.1 6.9 1.4 5.3 11.5 3.5 1.2 3.5
 Low volume 25.5 1.9 6.4 1.4 4.5 11.8 3.3 1.1 3.3
Teaching-Location
 Rural 24.4 1.8 5.2 1.3 3.3 12.3 3.1 1.1 3.2
 Urban teaching 25.9 1.7 6.4 1.3 5.1 12.3 3.1 1.2 3.2
 Urban non-teaching 26.6 2.3 7.4 1.5 5.4 10.9 3.8 1.1 3.7
Region
 Northeast 26.2 2.0 7.0 2.0 5.3 10.1 4.9 1.3 3.2
 Midwest 25.8 2.0 6.3 1.3 4.9 11.7 3.3 1.1 3.5
 South 25.4 2.0 6.7 1.1 5.0 11.4 2.8 1.1 3.3
 West 27.6 2.2 7.2 1.3 4.9 13.4 3.4 1.1 3.5
Bonferroni corrected p-values taken from two-sided Chi-squared tests were significant for all considered covariates, comparing patients without a 
complication to (1) patients with one or more complications overall as well as to (2) patients with one or more complications corresponding to each 
system-based complication group.
Abbreviations: CCI = Charlson Comorbidity Index
AValues shown reflect the year 2011 (2011 USD), some variation each year with values coded by NIS
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Table 3.
Risk-adjusted predicted mean incremental complication costs (95%CI) in 2017 USDA,B (independent of other 
included complications)
Cost of Major Oncologic Resections for Corresponding Malignant Diagnosis
 No complication Any complication Mechanical wound Infection Urinary
 (base value) (incremental cost) (incremental cost) (incremental cost) (incremental cost)
Esophagus $41,965.52
($39,600-44,400)
$40,373.00
($37,400-43,400)
p<0.001
$24,567.81
($19,900-29,300)
p<0.001
$46,583.13
($42,100-51,100)
p<0.001
$10,137.61
($0-23,600)
p=0.140
Stomach $31,294.51
($30,400-32,200)
$34,327.54
($32,400-36,300)
p<0.001
$18,974.45
($15,700-22,300)
p<0.001
$32,655.44
($30,600-34,700)
p<0.001
$3,270.68
($0-7,000)
p=0.087
Colon $19,134.92
($18,900-19,400)
$15,486.34
($15,100-15,900)
p<0.001
$11,810.92
($11,100-12,500)
p<0.001
$17,452.93
($17,000-17,900)
p<0.001
$3,124.35
($2,400-3,800)
p<0.001
Liver $24,545.76
($23,600-25,500)
$28,084.65
($25,800-30,400)
p<0.001
$14,039.63
($10,700-17,400)
p<0.001
$26,998.96
($24,600-29,400)
p<0.001
$8,028.56
($3,500-12,500)
p<0.001
Pancreas $34,948.59
($33,700-36,100)
$29,955.04
$28,100-31,800)
p<0.001
$16,828.88
($13,700-20,000)
p<0.001
$29,338.55
($27,100-31,600)
p<0.001
$8,630.08
($3,600-13,600)
p=0.001
Rectum $22,389.27
($21,700-23,000)
$12,738.36
($10,700-14,700)
p<0.001
$10.458.97
($6,900-14,100)
p<0.001
$14,209.97
($11,400-17,000)
p<0.001
$1,219.58
($0-4,600)
p=0.474
All
operations
$21,438.63
($21,000-21,700)
$20,889.63
($20,300-21,500)
p<0.001
$13,632.87
($12,900-14,300)
p<0.001
$21,640.12
($21,000-22,200)
p<0.001
$3,514.51
($2,700-4,400)
p<0.001
Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
(incremental cost) (incremental cost) (incremental cost) (incremental cost) (incremental cost)
Esophagus $21,744.40
($18,600-24,900)
p<0.001
$18,521.98
($14,800-22,300)
p<0.001
$9,376.70
($6,000-12,700)
p=0.001
$13,293.32
($3,400-23,200)
p=0.009
$10,733.90
($6,500-15,000)
p<0.001
Stomach $21,393.14
($19,700-23,100)
p<0.001
$14,798.45
($13,100-16,500)
p<0.001
$11,201.20
($9,100-13,300)
p<0.001
$8,730.07
($5,500-11,900)
p<0.001
$9,410.60
($7,200-11,600)
p<0.001
Colon $11,890.64
($11,400-12,400)
p<0.001
$5,958.92
($5,700-6,300)
p<0.001
$7,778.60
($7,300-8,300)
p<0.001
$4,699.68
($3,800-5,600)
p<0.001
$6,823.41
($6,300-7,300)
p<0.001
Liver $17,749.46
($15,100-20.400)
p<0.001
$9,207.44
($7,600-10,800)
p<0.001
$9,334.82
($7,100-11,600)
p<0.001
$3,805.61
($100-7,600)
p=0.048
$14,062.81
($11,500-16,600)
p<0.001
Pancreas $18,494.55
($16,100-20,900)
p<0.001
$10,733.72
($8,900-12,600)
p<0.001
$9,509.78
($6,900-12,100)
p<0.001
$3,858.17
($0-8,000)
p=0.068
$15,148.29
($12,800-17,500)
p<0.001
Rectum $4,870.77
($1,100-8,700)
p=0.012
$5,575.90
($3,900-7,300)
p<0.001
$10,375.04
($4,100-16,600)
p=0.001
$2,878.68
($0-11,600)
p=0.517
$8.094.11
($4,700-11,500)
p<0.001
All
operations
$16,809.14
($16,200-17,400)
p<0.001
$6,713.84
($6,300-10,300)
p<0.001
$9,733.42
($9,200-10,300)
p<0.001
$6,326.87
($5,400-7,300)
p<0.001
$9,009.16
(8,500-9,500)
p<0.001
A
Models accounted for potential confounding due to patient characteristics (age, sex, race/ethnicity, insurance type, median income quartile, 
indication, primary diagnosis, CCI, and year) and hospital-level factors (hospital volume, teaching-location, and geographical region). Calculation 
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of incremental additions also accounted for the potential influence of multiple complications by adjusting for the occurrence of all other 
complications to yield isolated, complication-specific effects.
B
Modeling used NIS-provided population weights generalized with STATA’s “svy” command to account for patient clustering within hospital-level 
variables and to extrapolate the sample to a nationally representative version of the US population. Predicted mean differences were calculated 
using post-estimation marginal effects following GLM with link log, family gamma, to account for the highly-skewed nature of the data.
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Table 4.
Risk-adjusted surgical outcomes (all operations)
Risk-adjusted OR1/predicted mean difference (95% CI)B
Outcome Any complication Mechanical wound Infection Urinary Pulmonary Gastrointestinal Cardiovascular Systemic Surgical
Non-routine 2.65 (2.58-2.72) 3.03 (2.81-3.27) 5.18 (4.91-5.46) 1.51 (1.40-1.63) 2.44 (2.31-2.57) 1.51 (1.46-1.56) 1.87 (1.77-1.99) 1.87 (1.77-1.99) 1.52 (1.44-1.59)
discharge
In-hospital 6.08 (5.79-6.39) 0.95 (0.84-1.07) 8.60 (8.13-9.11) 1.36 (1.17-1.58) 2.93 (2.73-3.15) 1.01 (0.95-1.08) 2.55 (2.34-2.78) 2.45 (2.14-2.82) 2.08 (1.90-2.27)
mortality
LOSA (days) 5.54 (5.45-5.64) 4.80 (4.61-4.99) 6.47 (6.35-6.61) 1.31 (1.10-1.52) 3.41 (3.27-3.54) 3.64 (3.55-3.74) 2.01 (1.87-2.15) 1.25 (1.00-1.51) 1.83 (1.69-1.98)
Abbreviation: LOS - length of stay
Modeling used NIS-provided population weights generalized with STATA’s “svy” command to account for patient clustering within hospital-level 
variables and to extrapolate the sample to a nationally representative version of the US population.
Interpretation: Risk-adjusted odds of non-routine discharge (in-hospital mortality) are x times higher among patients with a given type of 
complication relative to patients without that type of complication; Risk-adjusted predicted mean length of stay is x amount higher among patients 
with a given type of complication relative to patients without that type of complication.
A
To account for non-nonnally distributed data, modified Park tests were used to determine selection of a gamma distribution (lambda not 
significantly different from 2). Predicted mean differences were calculated using post-estimation average marginal effects following GLM with link 
log, family gamma.
B
Risk-adjusted models accounted for potential confounding due to other complications, patient characteristics (age, sex, race/ethnicity, insurance 
type, median income quartile, indication, primary diagnosis, CCI, and year), and hospital-level factors (hospital volume, teaching-location, and 
geographical region).
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